Alternative to Chemotherapy

AB001: Radical Innovation in Immuno-Oncology Therapy

Non-Chemo, Immuno-Gene Therapy targeting mRNA


AB001 inhibits miRNA Biogenesis Process 

AB001’s important therapeutic is its binding with RNA. Due to the femtogram and picogram levels of AB001 achieved in plasma, AB001 enters the target cells and alters the function of RNA. At the transcriptional level, AB001 binds in the binding pockets of RNA and blocks its transcriptional activity which leads to prevention of tumorigenesis. At the molecular level, AB001 alters micro-RNA (miRNA) and regulates its gene function.

AB001 Unique Features
      1. Negligible toxicity and no observable side effects
      2. Inhibits the miRNA biogenesis process
      3. Targets only cancer cells. No harm to normal cells
      4. Targets cancer stem cells and degrades them
      5. Inhibits multiple checkpoints including PD-L1
      6. Inhibits beta-catenin transcriptional activity to overcome the resistance and relapse
      7. Triggers apoptosis via MEK/JAK/STAT via the PI3K pathway
      8. No relapse has been observed in vivo 

AB001 PD1/PDL1 Inhibition

AB001 is a novel small molecule inhibitor that actively targets multiple pathways in cancer cells. It targets and binds specifically with PD-L1 on tumor cells and inhibits the downstream signaling of the PD-1 pathway that can restore the normal function of T cells.

Blockage of PD-1/PD-L1 interaction results in the reversal of the exhausted T-cell phenotype and normalization of antitumor response, providing the rationale of targeted therapy. It also stimulates B cells to secrete tumor-eliminating antibodies and inhibits the suppression of regulatory cells by Inhibiting IL-10 and TGF beta.

Pathways Inhibited by AB001

Being a small molecule it easily transverses through the plasma membrane and targets multicellular pathways such as WNT/β Catenin, PI3K, MAPK pathway, which are mainly involved in cellular proliferation survival and resistance.

None of the currently available chemo drugs target cancer stem cells due to their slow-growing ability, fast differentiation and expansion, which are responsible for relapse and recurrence.

AB001 is the first small molecule that eliminates cancer stem cells from the root via the beta-catenin pathway and degrades them. Furthermore, toxicity studies prove the safety of the molecule making it a promising alternative candidate for chemotherapy.

AB001 Overcoming Resistance

of Immune Checkpoint Inhibitors